Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
Luca Licata(Vita-Salute San Raffaele University), Giampaolo Bianchini(Vita-Salute San Raffaele University), Giuseppe Curigliano(European Institute of Oncology), Oreste Gentilini(San Raffaele University of Rome), Fabio Puglisi(University of Udine), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Lajos Pusztai(Yale University), Oluchi Oke(The University of Texas MD Anderson Cancer Center), Filippo Montemurro(Roche (Switzerland)), Lorenzo Sica(IRCCS Ospedale San Raffaele), Mariana Chávez‐MacGregor(The University of Texas MD Anderson Cancer Center), Stefano Cascinu(Vita-Salute San Raffaele University), Lorenzo Gerratana(National Cancer Institute), Mario Giuliano(Regione Campania), Giulia Viale(Istituti di Ricovero e Cura a Carattere Scientifico), Lucia Del Mastro(Ospedale Policlinico San Martino), Alessia Rognone(IRCCS Ospedale San Raffaele), Joseph Collins(South Carolina Oncology Associates), Antonio Giordano(Harvard University), Carmen Criscitiello(University of Milan), Sara Giordano(Harvard University), Julia Foldi(University of Pittsburgh)
Cited by 18
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k